Literature DB >> 32721816

Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma.

Qiaoli Wang1, Guoqiang Xu2, Yaoxiong Xia3, Jia Zuo3, Guilin Zeng4, Zhihong Xue4, Ruixue Cao3, Wei Xiong5, Wenhui Li6.   

Abstract

BACKGROUND: Induction chemotherapy plus concurrent chemoradiotherapy (IC + CCRT) is a standard treatment regimen for locally advanced nasopharyngeal carcinoma (LA-NPC). However, the increased acute toxicity of this intensified chemotherapy may counteract its efficacy. The results of studies focusing on the omission of concurrent chemotherapy (CC) regimens are controversial. Therefore, we carried out a meta-analysis to elucidate the efficacy and toxicity of IC + CCRT versus IC plus radiotherapy alone (IC + RT) for LA-NPC.
METHODS: Studies available on PubMed, Embase, Cochrane Library and ClinicalTrails.gov were independently searched by two investigators from inception to March 1, 2020. Review Manager software 5.3 (RevMan 5.3) was employed to calculate pooled hazard ratios (HRs), risk ratios (RRs) and 95% confidence intervals (CIs).
RESULTS: Eight studies with a total of 2605 patients were analysed. The results showed that no significant difference between IC + RT and IC + CCRT for disease-free survival (HR = 1.09, 95% CI: 0,85-1.39, P = 0.50), overall survival (HR = 0.92, 95% CI: 0.78-1.09, P = 0.34), local recurrence-free survival (HR = 1.26, 95% CI: 0.95-1.67; P = 0.10), or distant metastasis-free survival (HR = 1.03, 95% CI: 0.84-1.26, P = 0.79). Notably, the incidence of treatment-related grade 3/4 acute haematological toxicity during radiation was higher in the IC + CCRT group. Subgroup analysis showed similar survival outcomes for IC + CCRT and IC + RT with and without the two-dimensional RT technique.
CONCLUSIONS: IC + RT was as effective as IC + CCRT for the management of LA-NPC. The IC + RT regimen has the possibility of replacing the IC + CCRT regimen for LA-NPC in the future due to the lower toxicity, although more high-level evidence is urgently needed for verification.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Induction chemotherapy plus concurrent chemoradiotherapy; Induction chemotherapy plus radiotherapy; Meta-analysis; Nasopharyngeal carcinoma

Year:  2020        PMID: 32721816     DOI: 10.1016/j.oraloncology.2020.104925

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  6 in total

Review 1.  Which treatment is better than concurrent chemoradiotherapy about survival for stage III or IV locally advanced nasopharyngeal carcinoma? An updated Bayesian network meta-analysis of randomized controlled trials.

Authors:  Lucheng Fang; Licai Shi; Wen Wang; Tingting Hu; Xingwang Rao
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-02-17       Impact factor: 2.503

2.  Nomogram Predicting the Benefits of Adding Concurrent Chemotherapy to Intensity-Modulated Radiotherapy After Induction Chemotherapy in Stages II-IVb Nasopharyngeal Carcinoma.

Authors:  Sai-Lan Liu; Xue-Song Sun; Zi-Jian Lu; Qiu-Yan Chen; Huan-Xin Lin; Lin-Quan Tang; Jin-Xin Bei; Ling Guo; Hai-Qiang Mai
Journal:  Front Oncol       Date:  2020-11-09       Impact factor: 6.244

3.  Comparison of TPF and TP Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma Based on TNM Stage and Pretreatment Systemic Immune-Inflammation Index.

Authors:  Ying Xiong; Liangliang Shi; Lisheng Zhu; Gang Peng
Journal:  Front Oncol       Date:  2021-09-20       Impact factor: 6.244

4.  Radiomics Nomogram Based on Multiple-Sequence Magnetic Resonance Imaging Predicts Long-Term Survival in Patients Diagnosed With Nasopharyngeal Carcinoma.

Authors:  Kai Liu; Qingtao Qiu; Yonghui Qin; Ting Chen; Diangang Zhang; Li Huang; Yong Yin; Ruozheng Wang
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

5.  Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.

Authors:  Zhining Yang; Zeman Cai; Qingxin Cai; Yingji Hong; Cuidai Zhang; Kaichun Huang; Zhixiong Lin; Mei Li
Journal:  Cancer Med       Date:  2021-05-06       Impact factor: 4.452

6.  Construction of nomograms for nasopharyngeal carcinoma containing primary tumor size and SEER stage.

Authors:  Guangrong Yang; Bangyu Luo; Qiao Yang; Mingjing Chen; Xiu Yang; Jianguo Sun
Journal:  Transl Cancer Res       Date:  2020-11       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.